Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial

BACKGROUND: The antibacterial, anti-inflammatory, and antiviral properties of azithromycin suggest therapeutic potential against COVID-19. Randomised data in mild-to-moderate disease are not available. We assessed whether azithromycin is effective in reducing hospital admission in patients with mild...

Descripción completa

Detalles Bibliográficos
Autores principales: Hinks, Timothy S C, Cureton, Lucy, Knight, Ruth, Wang, Ariel, Cane, Jennifer L, Barber, Vicki S, Black, Joanna, Dutton, Susan J, Melhorn, James, Jabeen, Maisha, Moss, Phil, Garlapati, Rajendar, Baron, Tanya, Johnson, Graham, Cantle, Fleur, Clarke, David, Elkhodair, Samer, Underwood, Jonathan, Lasserson, Daniel, Pavord, Ian D, Morgan, Sophie, Richards, Duncan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8270523/
https://www.ncbi.nlm.nih.gov/pubmed/34252378
http://dx.doi.org/10.1016/S2213-2600(21)00263-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8270523/
https://www.ncbi.nlm.nih.gov/pubmed/34252378
http://dx.doi.org/10.1016/S2213-2600(21)00263-0

Ejemplares similares